Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46)

BACKGROUND: Tigilanol tiglate, a short-chain diterpene ester, is being developed as intratumoral treatment of a broad range of cancers. We conducted the first-in-human study of intratumoral tigilanol tiglate in patients with solid tumors. METHODS: Tigilanol tiglate was administered in a multicentre,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EBioMedicine
Autors principals: Panizza, Benedict J., de Souza, Paul, Cooper, Adam, Roohullah, Aflah, Karapetis, Christos S., Lickliter, Jason D.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2019
Matèries:
Research paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6921293/
https://ncbi.nlm.nih.gov/pubmed/31810818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.11.037
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars